Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
- Author
- JÄNNE, Pasi A; JOHNSON, Bruce E
[1] Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, United States
[2] Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States - Conference title
- Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005
- Conference name
- Cambridge Conference on Novel Agents in the Treatment of Lung Cancer: Advances in EGFR-Targeted Agents (3 ; Cambridge, Massachusetts 2005-09-23)
- Author (monograph)
- LYNCH, Thomas J (Editor)1 ; ENGELMAN, Jeffrey A (Editor)2 ; EVANS, Tracey L (Editor)3 ; JACKMAN, David (Editor)4 ; MARTINS, Renato G (Editor)5
[1] Center for Thoracic Cancers, Massachusetts General Hospital, Boston, Massachusetts, United States
[2] Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States
[3] Division of Hematology/Oncology, Medical Center-Presbyterian, Philadelphia, Pennsylvania, United States
[4] Dana Farber Cancer Institute, Boston, Massachusetts, United States
[5] Thoracic/Head and Neck Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States - Source
Clinical cancer research. 2006, Vol 12, Num 14 ; 4416s-4420s ; 2 ; ref : 39 ref
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Cancer du poumon Carcinome non petite cellule bronchopulmonaire Génétique Homme Inhibiteur enzyme Mutation Pronostic Protein-tyrosine kinase Récepteur facteur croissance épiderme Récepteur facteur croissance Traitement Inhibiteur de la tyrosine kinase Appareil respiratoire pathologie Bronche pathologie Enzyme Poumon pathologie Transferases Tumeur maligne
- Keyword (en)
- Lung cancer non-small cell lung carcinoma Genetics Human Enzyme inhibitor Mutation Prognosis Protein-tyrosine kinase Epidermal growth factor receptor Growth factor receptor Treatment Tyrosine kinase inhibitor Respiratory disease Bronchus disease Enzyme Lung disease Transferases Malignant tumor
- Keyword (es)
- Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Genética Hombre Inhibidor enzima Mutación Pronóstico Protein-tyrosine kinase Receptor factor crecimiento epidermi Receptor factor crecimiento Tratamiento Inhibidor tyrosine kinase Aparato respiratorio patología Bronquio patología Enzima Pulmón patología Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18041721
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-06-0555 
https://dx.doi.org/10.1158/1078-0432.CCR-06-0555
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:2:\"14\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:11:\"4416s-4420s\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"J\u00c4NNE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Pasi A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:16:\"JOHNSON, Bruce E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:174:\"Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005\";s:8:\"\u0000*\u0000title\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:2:\"14\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:11:\"4416s-4420s\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"J\u00c4NNE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Pasi A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:16:\"JOHNSON, Bruce E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:174:\"Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005\";s:8:\"\u0000*\u0000title\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:2:\"14\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:11:\"4416s-4420s\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"J\u00c4NNE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Pasi A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:16:\"JOHNSON, Bruce E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:174:\"Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005\";s:8:\"\u0000*\u0000title\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:2:\"14\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:11:\"4416s-4420s\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"J\u00c4NNE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Pasi A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:16:\"JOHNSON, Bruce E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:174:\"Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005\";s:8:\"\u0000*\u0000title\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-06-0555\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Clinical cancer research\";s:9:\"\u0000*\u0000stitle\";s:16:\"Clin. cancer res\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:2:\"14\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:11:\"4416s-4420s\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"J\u00c4NNE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Pasi A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:16:\"JOHNSON, Bruce E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:174:\"Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005\";s:8:\"\u0000*\u0000title\";s:209:\"Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non - small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
